Investigating the in vivo bioequivalence of losartan 50 mg
Not Applicable
- Conditions
- In the present study, the products will be administered to healthy volunteers..
- Registration Number
- IRCT20210519051345N23
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
General Health (in terms of Liver, Heart and Kidney)
Exclusion Criteria
Smoking
History of cardiovascular disease, liver and kidney disease
Pregnancy
Alcohol and drug addiction
History of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of drug. Timepoint: 0.5-24 hours in predetermined time intervals after drug administration. Method of measurement: HPLC (High performance liquid chromatography).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of losartan's AT1 receptor antagonism are compared in IRCT20210519051345N23 bioequivalence study?
How does Ronak Co.'s losartan 50 mg capsule compare to the innovator in pharmacokinetic profiles for hypertension management?
Which biomarkers correlate with losartan efficacy in bioequivalence trials involving angiotensin II receptor blockers (ARBs)?
What adverse event management strategies are associated with losartan 50 mg formulations in healthy volunteer studies?
How does the bioequivalence of Ronak Co. losartan capsules impact ARB class therapeutic interchangeability in cardiovascular care?